Exelixis, Inc. (NASDAQ:EXEL) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Exelixis, Inc. (NASDAQ:EXEL) have been assigned a consensus recommendation of “Moderate Buy” from the nineteen analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $36.06.

A number of brokerages have commented on EXEL. Wells Fargo & Company increased their price objective on shares of Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Exelixis in a research note on Monday, January 27th. The Goldman Sachs Group raised shares of Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. Brookline Capital Management began coverage on Exelixis in a report on Monday, December 23rd. They set a “buy” rating on the stock. Finally, Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $30.00 to $40.00 in a research note on Monday, January 27th.

Insider Activity

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the sale, the executive vice president now directly owns 278,665 shares in the company, valued at approximately $9,828,514.55. The trade was a 3.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,588 shares of company stock worth $3,981,864 over the last three months. Corporate insiders own 2.85% of the company’s stock.

Institutional Trading of Exelixis

Several institutional investors and hedge funds have recently bought and sold shares of EXEL. V Square Quantitative Management LLC acquired a new position in shares of Exelixis during the 3rd quarter worth approximately $30,000. USA Financial Formulas acquired a new position in Exelixis during the fourth quarter worth $32,000. Principal Securities Inc. raised its position in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares in the last quarter. Kestra Investment Management LLC acquired a new stake in Exelixis in the fourth quarter valued at $39,000. Finally, Brooklyn Investment Group bought a new position in shares of Exelixis in the 3rd quarter valued at about $42,000. Institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

EXEL stock opened at $33.55 on Thursday. The business has a fifty day moving average price of $34.50 and a 200 day moving average price of $30.35. Exelixis has a fifty-two week low of $20.01 and a fifty-two week high of $37.59. The stock has a market capitalization of $9.58 billion, a price-to-earnings ratio of 21.51, a P/E/G ratio of 0.72 and a beta of 0.53.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.